| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8865937 | ALLERGAN | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43879 | ALLERGAN | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Jan, 2026
(2 years from now) | |
| US8481598 | ALLERGAN | Stable dosage forms of levomilnacipran |
Mar, 2031
(7 years from now) | |
Fetzima is owned by Allergan.
Fetzima contains Levomilnacipran Hydrochloride.
Fetzima has a total of 3 drug patents out of which 0 drug patents have expired.
Fetzima was authorised for market use on 25 July, 2013.
Fetzima is available in capsule, extended release;oral dosage forms.
Fetzima can be used as treatment of major depressive disorder (mdd).
The generics of Fetzima are possible to be released after 23 May, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Oct 7, 2022 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
FETZIMA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic